LYN-00101
/ Lynkcell
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
March 11, 2020
Safety and Efficacy of the Fully Humanized Anti - VEGF Monoclonal Antibody LYN00101
(clinicaltrials.gov)
- P1; N=0; Withdrawn; Sponsor: Lynkcell Inc.; N=19 ➔ 0; Trial completion date: Feb 2020 ➔ Aug 2020; Active, not recruiting ➔ Withdrawn; Trial primary completion date: Nov 2019 ➔ Jun 2020
Clinical • Enrollment change • Trial completion date • Trial primary completion date • Trial withdrawal • CRP • MRI
1 to 1
Of
1
Go to page
1